At 8.3% CAGR, the South & Central America Lyophilization Services for Biopharmaceuticals Market is projected to be worth US$ 104.37 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America lyophilization services for biopharmaceuticals market was valued at US$ 70.02 million in 2023 and is expected to reach US$ 104.37 million by 2028, registering a CAGR of 8.3% from 2023 to 2028. Rising demand for lyophilized products and rapid growth in contract manufacturing and lyophilization services are among the critical factors attributed to the South & Central America lyophilization services for biopharmaceuticals market expansion.             

Biopharmaceutical companies in the lyophilization services market are launching advanced lyophilization technologies to expand their business and maintain a competitive environment in the market. In May 2022, PCI Pharma Services (PCI), a leading global CDMO, announced a major expansion of capacity and capabilities in sterile lyophilization technology and aseptic liquid fill-finish, an important manufacturing process commonly used with injectable and biologic therapies, with the investment of US$100 million in the construction and enhancement of world-class facilities at its Bedford, New Hampshire campus. The facility will contain state-of-the-art technology, including an aseptic fill-finish line with a completely isolated containment system. Also, it will hold twin lyophilizers with auto loading and unloading systems, with the capacity to complete 400 vials/minute on a sterile fill-finish line, aiding boost the growth of market so that patients receive therapies faster. The launch of such advanced lyophilization technologies is likely to offer opportunities for the South & Central America lyophilization service for biopharmaceuticals market players to attain a significant position in the coming years.

On the contrary, demerits associated with lyophilization process hampers on the growth of South & Central America lyophilization services for biopharmaceuticals market. 

Based on service type, the South & Central America lyophilization services for biopharmaceuticals market is segmented into lyophilization cycle development, clinical manufacturing, commercial manufacturing, and freeze drying analytical services. The commercial manufacturing segment held 29.5% share of South & Central America lyophilization services for biopharmaceuticals market in 2023, amassing US$ 20.67 million. It is projected to garner US$ 29.07 million by 2028 to expand at 7.1% CAGR during 2023–2028.

Based on end user, the South & Central America lyophilization services for biopharmaceuticals market is segmented into pharmaceutical & biotechnology companies, research institutes, and other. The pharmaceutical & biotechnology companies segment held 76.5% share of South & Central America lyophilization services for biopharmaceuticals market in 2023, amassing US$ 53.54 million. It is projected to garner US$ 80.30 million by 2028 to expand at 8.4% CAGR during 2023–2028.

Based on country, the South & Central America lyophilization services for biopharmaceuticals market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 56.1% share of South & Central America lyophilization services for biopharmaceuticals market in 2023. It was assessed at US$ 39.26 million in 2023 and is likely to hit US$ 62.75 million by 2028, exhibiting a CAGR of 9.8% during 2023–2028.            

Key players operating in the South & Central America lyophilization services for biopharmaceuticals market are ABB, Azbil Corporation, Curia Global Inc, Grifols S.A., Jubilant HollisterStier LLC., and OPTIMA, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com